Log in

ATEC Alphatec Holdings, Inc. NASDAQ · United States

Alphatec Holdings (ATEC) news

Latest Alphatec Holdings news

We have not published a story on Alphatec Holdings yet. When there is news, it will appear here.

Alphatec Holdings annual financials

LineFY2025FY2024
Net income (loss)-$143.4 million-$162.1 million
Cash from operations$45.2 million-$44.7 million
Cash and equivalents$160.8 million$138.8 million

Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $79.9 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Alphatec Holdings

What is the ticker symbol of Alphatec Holdings?

Alphatec Holdings, Inc. trades under the ticker ATEC on NASDAQ.

Where is Alphatec Holdings listed?

Alphatec Holdings, Inc. is listed on NASDAQ.

Which country or territory is Alphatec Holdings listed under?

Our directory records Alphatec Holdings, Inc. under United States.

Does aibio.space cover Alphatec Holdings?

aibio.space lists Alphatec Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Alphatec Holdings profitable?

Alphatec Holdings, Inc. reported a net loss of $143.4 million for the fiscal year ended Dec 31, 2025, and generated $45.2 million of cash from operations, per its annual report to the SEC.

How much cash does Alphatec Holdings have?

$79.9 million in cash at Sep 30, 2026, per its 10-Q.

What is the latest Alphatec Holdings (ATEC) stock news?

Our latest story on Alphatec Holdings, dated May 1, 2026: "Alphatec signs $175.0 million term loan and $125.0 million revolver". JPMorgan Chase Bank, N.A. is administrative agent on the $175.0 million term loan A and the $125.0 million revolver, which repaid older credit agreements. Source.

Does Alphatec Holdings have debt, a term loan or convertible notes?

Our latest debt story, dated May 1, 2026: "Alphatec signs $175.0 million term loan and $125.0 million revolver". JPMorgan Chase Bank, N.A. is administrative agent on the $175.0 million term loan A and the $125.0 million revolver, which repaid older credit agreements. Source.

How can I follow Alphatec Holdings (ATEC) news?

Press Follow on this page to add Alphatec Holdings to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Alphatec Holdings so far, in Debt Financing.

Investor discussion: Alphatec Holdings

Members talk about Alphatec Holdings (ATEC). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ATEC on TradingView.

Listing details

Alphatec Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ATEC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Alphatec Holdings, Inc.
Ticker
ATEC
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.